Aspirin has little additional anti‐platelet effect in healthy volunteers receiving prasugrel
Open Access
- 21 July 2011
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 9 (10) , 2050-2056
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial InfarctionCirculation, 2011
- In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregationJournal of Thrombosis and Haemostasis, 2010
- Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?: Figure 1Heart, 2010
- Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapyJournal of Thrombosis and Haemostasis, 2010
- The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) StudyJACC, 2008
- Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2Journal of Thrombosis and Haemostasis, 2008
- Two Waves of Platelet Secretion Induced by Thromboxane A2 Receptor and a Critical Role for Phosphoinositide 3-KinasesJournal of Biological Chemistry, 2003
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE studyThe Lancet, 2001
- Molecular Mechanism of Thromboxane A2-induced Platelet AggregationJournal of Biological Chemistry, 1999